GELSNasdaqPharmaceutical PreparationsUS GAAP · USD

Gelteq Ltd

Gelteq Ltd is a U.S.-listed pharmaceutical preparations company that develops and commercializes dosage-formulation and drug-delivery solutions through its corporate and financing structure. The company’s disclosed activity centers on raising capital and issuing securities to support its operating and development needs.

Ask about the company

Business

Share of revenue
Pharmaceutical preparations60 %

Finished dosage-form pharmaceutical products and related formulations.

Drug-delivery technology25 %

Delivery systems and formulation platforms that support product administration.

Corporate financing and equity issuance15 %

Convertible notes and related securities issued to fund operations.

Customers

Gelteq’s primary buyers would be pharmaceutical and healthcare counterparties that license, distribute, or use its formulation and delivery capabilities. Depending on the commercialization model, demand would also come from institutional investors and financing partners that provide capital through notes and equity-linked instruments.

Pharmaceutical partners

Buy formulation or delivery capabilities for development or commercialization.

Healthcare distributors

Buy or distribute finished preparations for end-market access.

Institutional financiers

Provide convertible debt capital and associated funding structures.

Equity investors

Provide growth capital and absorb dilution risk from securities issuance.

Strategy

The disclosed strategy is to secure financing and maintain flexibility to issue shares in connection with convertible notes. This supports the company’s ability to fund product development, working capital, and any commercialization or corporate initiatives while using equity-linked capital where needed.

Secure financing capacityShort term

Convertible notes provide operating liquidity and funding flexibility.

Manage dilution and issuance termsShort term

Equity-linked funding affects ownership and future financing capacity.

Maintain market accessMedium term

Nasdaq compliance and approvals matter for future capital raises.

Geography

The company is identified as a United States issuer, with meeting and financing disclosures referencing Australia and Nasdaq-related matters. The available reports do not provide a revenue geography split, so the business should be viewed as operating with an international capital-markets footprint rather than a clearly disclosed commercial revenue map.

Risks

The most visible company-specific risk is dilution from convertible-note financing, which can materially expand share count as notes are converted or otherwise settled. As a pharmaceutical preparations company, Gelteq also faces typical development, commercialization, and regulatory execution risk, while relying on external financing increases sensitivity to market access and capital availability.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Convertible-note dilution1Capital access risk2Pharma development risk3Nasdaq compliance risk4
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Convertible-note dilutionImpact: HighLikelihood: High

    Shares can be issued on conversion or settlement of principal, interest, fees, and premiums.

    Exposure: Existing shareholders and voting power

  2. Capital access riskImpact: HighLikelihood: High

    The business depends on repeat financing to fund operations and growth.

    Exposure: Liquidity and ongoing operations

  3. Pharma development riskImpact: HighLikelihood: Medium

    Pharmaceutical preparations businesses depend on technical, regulatory, and commercial success.

    Exposure: Product development and commercialization

  4. Nasdaq compliance riskImpact: MediumLikelihood: Medium

    Equity issuance and shareholder approvals are linked to listing-rule requirements.

    Exposure: Listing access and financing flexibility

Ask Clarifo about Gelteq Ltd

Accounting

Judgemental items
Convertible notes

Note terms determine liability recognition, discount accretion, and any equity component.

Impact: Reported financing cost and leverage presentation

Original issue discount

The financing proceeds are net of discount, affecting effective borrowing cost.

Impact: Net proceeds and interest expense

Diluted shares outstanding

Potential conversion shares may increase diluted EPS and ownership metrics.

Impact: Per-share earnings and dilution analysis

Equity issuance limits

The 19.99% and 9.99% thresholds shape how issuances are recorded and authorized.

Impact: Share count and financing flexibility

Similar listed companies

Publicly listed companies with a comparable business focus.

CTT Pharmaceutical Holdings, Inc.

CTTH · Pharmaceutical Preparations

Provectus Biopharmaceuticals, Inc.

PVCT · Pharmaceutical Preparations

Pasithea Therapeutics Corp.

KTTA · Pharmaceutical Preparations

Curanex Pharmaceuticals Inc

CURX · Pharmaceutical Preparations

Elite Pharmaceuticals Inc /NV/

ELTP · Pharmaceutical Preparations

CDT Equity Inc.

CDTTW · Pharmaceutical Preparations

Last updated: 28/09/2026

Gelteq Ltd (Nasdaq) – Pharmaceutical Preparations | Financial Analysis – Clarifo